JPRN-UMIN000012057Completed未知
A clinical study on the safety of hypo-fractionated stereotactic intensity-modulated radiation therapy for prostate cancer - hypo-fractionated stereotactic intensity-modulated radiation therapy for prostate cancer
Department of Radiation Oncology & Image-applied Therapy, Kyoto University Graduate School of Medicine0 sites24 target enrollmentStarted: October 17, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
o grade 3 or higher acute toxicity was observed. With a minimum follow-up period of 2 years, no grade 2 or higher late toxicity was observed and the 2-year biochemical recurrence-free survival rate was 95.8%.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 50years-old to 80years-old (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Active double cancer 2) Uncontrolled diabetes mellitus (HbA1c>+8.4%) 3) Severe coexisting diseases such as collagen disease, heart disease, respiratory disease and liver disease. 4) Psychotic disease 5) History of pelvic irradiation 6) History of pelvic surgery except for appendectomy and femoral herniation. 7) Surgical managements to the prostate 8) Chemotherapy to the prostate cancer 9) Inflammatory bowel diseases 10) Cases who are difficult to discontinue the administration of anticoagulant drugs.
Investigators
Similar Trials
Completed
Not Applicable
A long term clinical study for safety evaluation of containing plant-extracts foods. (SME-2021-07)ot applicableJPRN-UMIN000047024Suntory Beverage & Food Limited48
Active, not recruiting
Phase 1
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-GBAlkermes Inc500
Active, not recruiting
Phase 1
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-IEAlkermes Inc500
Active, not recruiting
Phase 1
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-ATAlkermes Inc500
Active, not recruiting
Phase 1
Study to evaluate the long term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder.EUCTR2017-000918-36-BGAlkermes Inc500